Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer

Edward J. Tanner, Destin R. Black, Oliver Zivanovic, Siobhan M. Kehoe, Fanny Dao, Jason A. Konner, Richard R. Barakat, Stuart M. Lichtman, Douglas A. Levine

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. Methods: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. Results: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P = 0.018). Conclusions: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.

Original languageEnglish (US)
Pages (from-to)59-62
Number of pages4
JournalGynecologic Oncology
Volume124
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Adjuvant Chemotherapy
Ovarian Neoplasms
Recurrence
Drug Therapy
Abdomen
Pelvis
Abdominal Cavity
Platinum
Lymph Nodes
Databases

Keywords

  • Advanced ovarian cancer
  • First recurrence
  • High-grade serous
  • Intraperitoneal chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. / Tanner, Edward J.; Black, Destin R.; Zivanovic, Oliver; Kehoe, Siobhan M.; Dao, Fanny; Konner, Jason A.; Barakat, Richard R.; Lichtman, Stuart M.; Levine, Douglas A.

In: Gynecologic Oncology, Vol. 124, No. 1, 01.2012, p. 59-62.

Research output: Contribution to journalArticle

Tanner, EJ, Black, DR, Zivanovic, O, Kehoe, SM, Dao, F, Konner, JA, Barakat, RR, Lichtman, SM & Levine, DA 2012, 'Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer', Gynecologic Oncology, vol. 124, no. 1, pp. 59-62. https://doi.org/10.1016/j.ygyno.2011.09.011
Tanner, Edward J. ; Black, Destin R. ; Zivanovic, Oliver ; Kehoe, Siobhan M. ; Dao, Fanny ; Konner, Jason A. ; Barakat, Richard R. ; Lichtman, Stuart M. ; Levine, Douglas A. / Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. In: Gynecologic Oncology. 2012 ; Vol. 124, No. 1. pp. 59-62.
@article{ce39c11b33864eafaadb78cd0262fc1a,
title = "Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer",
abstract = "Objective: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. Methods: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. Results: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5{\%} versus 23.3{\%}, P = 0.018). Conclusions: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.",
keywords = "Advanced ovarian cancer, First recurrence, High-grade serous, Intraperitoneal chemotherapy",
author = "Tanner, {Edward J.} and Black, {Destin R.} and Oliver Zivanovic and Kehoe, {Siobhan M.} and Fanny Dao and Konner, {Jason A.} and Barakat, {Richard R.} and Lichtman, {Stuart M.} and Levine, {Douglas A.}",
year = "2012",
month = "1",
doi = "10.1016/j.ygyno.2011.09.011",
language = "English (US)",
volume = "124",
pages = "59--62",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer

AU - Tanner, Edward J.

AU - Black, Destin R.

AU - Zivanovic, Oliver

AU - Kehoe, Siobhan M.

AU - Dao, Fanny

AU - Konner, Jason A.

AU - Barakat, Richard R.

AU - Lichtman, Stuart M.

AU - Levine, Douglas A.

PY - 2012/1

Y1 - 2012/1

N2 - Objective: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. Methods: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. Results: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P = 0.018). Conclusions: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.

AB - Objective: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. Methods: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests. Results: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P = 0.018). Conclusions: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.

KW - Advanced ovarian cancer

KW - First recurrence

KW - High-grade serous

KW - Intraperitoneal chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=83055181179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055181179&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.09.011

DO - 10.1016/j.ygyno.2011.09.011

M3 - Article

C2 - 21982046

AN - SCOPUS:83055181179

VL - 124

SP - 59

EP - 62

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -